Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;96(8):e29822.
doi: 10.1002/jmv.29822.

Evaluation of cross-neutralizing immunity following COVID-19 primary series vaccination during the Omicron surge in Tanzania

Lilian Nkinda  1 , Godfrey Barabona  2 , Isaac Ngare  2 , Emmanuel Nkuwi  2   3 , Doreen Kamori  1   2 , Frank Msafiri  1 , Ponsian P Kunambi  1 , Elisha Osati  1   4 , Benson R Kidenya  5 , Harrison Chuwa  6 , Glory Kinasa  6 , Frank E Hassan  7 , George P Judicate  1   7 , Joseph Gasper  8 , Juma Kisuse  7 , Sayoki Mfinanga  7 , Mbazi Senkoro  7 , Takamasa Ueno  1   2 , Eligius Lyamuya  1 , Emmanuel Balandya  1
Affiliations

Evaluation of cross-neutralizing immunity following COVID-19 primary series vaccination during the Omicron surge in Tanzania

Lilian Nkinda et al. J Med Virol. 2024 Aug.

Abstract

COVID-19 vaccine became available in Tanzania during the first wave of the Omicron variant. During that time community seroprevalence of SARS-CoV-2 was already at 50%-80%. To date, it remains largely unknown whether ongoing vaccination with the primary series vaccines has any meaningful immune-boosting effects against newer Omicron subvariants. Therefore, we tested cross-neutralizing capacity of antibodies elicited by infection, vaccination, or both against SARS-CoV-2 Omicron subvariants BA.1, and the newer subvariants BQ.1.1 and XBB.1.5. that were unexperienced by this population. Participants who were either SARS-CoV-2 infected-only (n = 28), infected vaccinated (n = 22), or vaccinated-only (n = 73) were recruited from Dar-es-Salaam, Tanzania, between April and December 2022. Plasma 50% neutralization titers (NT50) against SARS-CoV-2 wild-type strain and Omicron subvariants were quantified by a lentiviral-based pseudo-virus assay. Percentage of participants with neutralizing activity against WT and BA.1 was high (>85%) but was reduced against BQ.1.1 (64%-77%) and XBB.1.5 (35%-68%) subvariants. The low median cross-neutralization titer was slightly higher in the infected vaccinated group compared to vaccine-only group against BQ.1.1 (NT50 148 vs. 85, p = 0.032) and XBB.1.5 (NT50 85 vs. 37 p = 0.022) subvariants. In contrast, vaccine-boost among the infected vaccinated did not result to increased cross-neutralization compared to infected-only participants (BQ.1.1 [NT50 of 148 vs. 100, p = 0.501] and XBB.1.5 [NT50 86 vs. 45, p = 0.474]). We report severely attenuated neutralization titers against BQ.1.1 and XBB.1.5 subvariants among vaccinated participants, which marginally improved in the infected vaccinated participants. Our findings call for further studies to evaluate effectiveness of the primary series vaccines in preventing severe infection and mortality against the newer variants.

Keywords: Africa; BQ.1.1; SARS‐CoV‐2; Tanzania; XBB.1.5; neutralizing antibodies.

PubMed Disclaimer

References

REFERENCES

    1. Burki T. WHO ends the COVID‐19 public health emergency. Lancet Respir Med. 2023;11:588. doi:10.1016/S2213-2600(23)00217-5
    1. Alam MS. Insight into SARS‐CoV‐2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities. Heliyon. 2023;9:e13285. doi:10.1016/j.heliyon.2023.e13285
    1. Evans RA, Dube S, Lu Y, et al. Impact of COVID‐19 on immunocompromised populations during the Omicron era: insights from the observational population‐based INFORM study. Lancet Reg Health Eur. 2023;35:100747. doi:10.1016/j.lanepe.2023.100747
    1. World Health Organisation. WHO releases global COVID‐19 vaccination strategy update to reach unprotected. 2022. https://www.who.int/news/item/22-07-2022-who-releases-global-covid-19-va...
    1. Keeton R, Richardson SI, Moyo‐Gwete T, et al. Prior infection with SARS‐CoV‐2 boosts and broadens Ad26.COV2.S immunogenicity in a variant‐dependent manner. Cell Host Microbe. 2021;29:1611‐1619. doi:10.1016/j.chom.2021.10.003

Supplementary concepts